[EN] UROTENSIN II RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR DE L'UROTENSINE II
申请人:ACADIA PHARM INC
公开号:WO2003104216A1
公开(公告)日:2003-12-18
Disclosed are compounds of Formula I, or salts or prodrugs thereof, complexed
with a human urotensin II receptor as defined herein. Also disclosed are compounds
of Formula II, or salts or prodrugs thereof, as defined herein. Also disclosed
are methods of modulating the activity of a urotensin II receptor using a compound
of Formula I, or a compound of Formula II, or salts or prodrugs thereof. In addition,
methods of treating diseases related to the activity of urotensin II receptors
are disclosed.
本文披露了根据本文所定义的与人类尿嘧啶 II 受体形成络合物的 Formula I 化合物,或其盐或前药。还披露了根据本文所定义的 Formula II 化合物,或其盐或前药。还披露了使用 Formula I 化合物、Formula II 化合物、或其盐或前药来调节尿嘧啶 II 受体活性的方法。此外,还披露了治疗与尿嘧啶 II 受体活性相关疾病的方法。
Boschman; De Winter, European Journal of Medicinal Chemistry, 1980, vol. 15, # 4, p. 351 - 356
作者:Boschman、De Winter
DOI:——
日期:——
Urotensin II receptor agents
申请人:——
公开号:US20040077529A1
公开(公告)日:2004-04-22
Disclosed are compounds of Formula I, or salts or prodrugs thereof, complexed with a human urotensin II receptor
1
as defined herein. Also disclosed are compounds of Formula II, or salts or prodrugs thereof,
2
as defined herein. Also disclosed are methods of modulating the activity of a urotensin II receptor using a compound of Formula I, or a compound of Formula II, or salts or prodrugs thereof. In addition, methods of treating diseases related to the activity of urotensin II receptors are disclosed.
Novel and potent small-molecule urotensin II receptor agonists
作者:Fredrik Lehmann、Erika A. Currier、Bryan Clemons、Lars K. Hansen、Roger Olsson、Uli Hacksell、Kristina Luthman
DOI:10.1016/j.bmc.2009.04.062
日期:2009.7
A series of analogs of the non-peptidic urotensin II receptor agonist N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide (FL104) has been synthesized and evaluated pharmacologically. The enantiomers of the two most potent racemic analogues were obtained from the corresponding diastereomeric mandelic amides. In agreement with previously observed SAR, most of the agonist potency resided